REC-2615 (HCl) is a α1B-adrenoceptor antagonist potentially for the treatment of female sexual dysfunction.

Asimadoline HCl is a κ-opioid receptor agonist potentially for the treatment of pruritus. Asimadoline has also been shown to be used in the treatment of irritable bowel syndrome.

Examorelin, also known as Hexarelin, is a growth hormone-releasing factor (GHRF) agonist potentially for the treatment of cardiac diseases.

Tocladesine is a cyclic adenosine monophosphate (cAMP) receptor agonist potentially for the treatment of colorectal cancer.

Fluasterone, also known as HE2500, is an NF-κB activation inhibitor potentially for the treatment of metabolic syndrome.

Apratastat, also known as TMI-005 and XMT-1191, is a matrix metalloproteinase/tumour necrosis factor-α convertase inhibitor.

An alpha2-adrenoceptor antagonist potentially for the treatment of schizophrenia.

Sipatrigine is a multiple channels blocker potentially for the treatment of stroke. It has been shown to blocks multiple cardiac ion channels, cause triangulation of the ventricular action potential,and could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1.

Sodium pyruvate is a antioxidant potentially for the treatment of chronic obstructive pulmonary disease

N-Acetylmannosamine, also known as ManNAc, DEX M-74, N-acetyl-D-mannosamine, is a drug potentially for the treatment of hereditary inclusion body myopathy

P-1075, also known as PNU-83757 and U-83757, is a K-ATP channel agonist potentially for the treatment of erectile dysfunction, alopecia and arrhythmia.

FdCyd is a DNA methyltransferase (DNMT) inhibitor potentially for the treatment of solid tumours.

Secoisolarisiresinol diglucoside (SDG) is potentially for the treatment of oxidative stress.

Ferroquine is a hemozoin inhibitor potentially for the treatment of malaria.

Equol is a drug is potentially for the treatment of acute thyroid disease and inhibits proliferation of human gastric carcinoma cells. Equol (racemic) is a mixture of S-equol and R-equol.

Celgosivir is an α-glucosidase inhibitor potentially for the treatment of dengue fever.

Sodium taurocholate is a GPBAR1 protein agonist potentially for the treatment of type 2 diabetes and obesity in rats.

Siramesine Fumarate is a sigma receptor agonist potentially for the treatment of generalized anxiety disorder

NGX-267 is a muscarinic M1 agonist potentially for the treatment of Xerostomia, Alzheimer's disease and cognitive

Pyridoxyl phosphate is a purinergic P2 receptor antagonist potentially for the treatment of tardive dyskinesia

ZD-0947, also known as AZD-0947, is a K(ATP) channel activator potentially for the treatment of overactive bladder (OAB).

Oxipurinol is a xanthine oxidase inhibitor potentially for the treatment of heart failure and gout.

GW 842166X is a cannabinoid receptor 2 (CB2) agonist potentially for the treatment of inflammatory pain.

Idremcinal is a motilin receptor agonist potentially for the treatment of gastritis

AIM-102 is nonsteroidal, immune modulating, anti-inflammatory drug potentially for the treatment of allergic asthma

SR-33805 is a calcium channel antagonist potentially for the treatment of atherosclerosis and heart failure. SR-33805 restored the MI-altered cell shortening without affecting the Ca(2+) transient amplitude, suggesting an increase of myofilament Ca(2+) sensitivity in MI myocytes. A SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin light chain-2 phosphorylation and a more significant decrease on troponin I (TnI) phosphorylation. Decreased TnI phosphorylation was related to inhibition of protein kinase A activity by SR-33805.

Bepafant, also known as WEB-2170 and STY-2108, is a platelet activating factor (PAF) antagonist potentially for the treatment of asthma. Bepafant triggered apoptosis in NB4, KG1, and NB4-MR4 cells where PTEN was expressed, but not in THP1 and U937 cells where PTEN was absent. Bepafant may produce significant anti-inflammatory effects.

Indole-3-propionic acid, also known as IPA and SHP-622, is a beta-amyloid protein neurotoxicity inhibitor potentially for the treatment of Friedreich's ataxia. The administration of IPA significantly decreased the level of 4-hydroxy-2-nonenal, a marker of lipid peroxidation, in ischemic hippocampal homogenates compared with that in the vehicle-treated ischemic groups at various times after ischemia/reperfusion. In addition, immunostaining for 8-hydroxy-2'-deoxyguanosine showed DNA damage in pyramidal neurons in the ischemic CA1 was significantly lower in the IPA-treated ischemic groups than in the vehicle-treated ischemic groups. IPA may be used as a pharmacological agent to protect against iron-induced oxidative damage to membranes and, potentially, against carcinogenesis.

Histapyrrodine hydrochloride is a bioactive chemical.

Lupulon, also known as Lupulone, is a beta-acid that has been found in the hop plant, H. lupulus, and has diverse biological activities, including antibacterial, antioxidant, and anticarcinogenic properties. Lupulone is active against B. subtilis and S. aureus as well as T. b. brucei and L. m. mexicana. It scavenges 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals and reduces proliferation, migration, and capillary tube formation in human umbilical vein endothelial cells (HUVECs). Lupulone also activates the extrinsic apoptotic death pathway in SW480 and SW620 colon cancer cells.